



LeukoDx Inc. Secures \$3.2 Million Financing

Towson, MD & Jerusalem, IL, October, 2013 – LeukoDx Inc. the innovator of Accellix, the fully automated flow cytometry platform, announced that it has successfully secured \$3.2 million in Series A2 and A3A financing. The financing was obtained from Axcel Partners, a US private equity group and some individual investors.

About LeukoDx Inc.

LeukoDx Inc. was founded in 2009. Its technology development is based on a novel flow cytometry platform initially developed for NASA at CalTech. LeukoDx's mission is to deliver cost-effective, highly sensitive and actionable diagnostic information at the point of care with its novel automated IVD flow cytometry platform. Working towards this goal, the company is developing a compact reader for single use test-specific cartridges. The first test application is for sepsis, associated with high morbidity and mortality and a large burden upon healthcare resources worldwide where no rapid and reliable diagnostic test exist today.

Contact:

Julien Meissonnier, President and CEO

Tel: +972-2-674-4422

Email: jmeissonnier@leukodx.com